Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss in the substantia nigra, which is accompanied by immune dysfunction and chronic inflammation. Peripheral monocytes, key players in systemic inflammation, cross the blood-brain barrier and alter PD etiology and progression. To define the role of peripheral monocytes, cross-sectional studies of RNA transcripts isolated from PD monocytes were compared with age- and sex-matched control monocytes.
View Article and Find Full Text PDFFront Public Health
July 2025
Psychological first aid programs aim to train lay people to help others who are experiencing a mental health crisis or developing mental health problems. The current article introduces the new German psychological first aid training program HSN. The acronym HSN stands for "Helfen in Seelischer Not" (helping in mental distress) but also for the action chain "hear, speak, network.
View Article and Find Full Text PDFAlzheimers Res Ther
July 2025
Background: We previously documented that regulatory T cells (Tregs) immunomodulatory mechanisms are compromised in Alzheimer's disease (AD), shifting the immune system toward a pro-inflammatory response. However, Tregs are a potentially restorable therapeutic target in AD. In this study, we evaluated the safety and efficacy of two dosing frequencies of low-dose Interleukin-2 (IL-2) in expanding Tregs to modify disease progression in AD individuals.
View Article and Find Full Text PDFLimited knowledge exist on HTN-related knowledge and health behaviors among African American adult stroke survivors with hypertension condition living in rural Alabama. To address this gap, we conducted a small pilot study with a mixed methods design for needs assessment of stroke survivors with a hypertension condition living in rural areas of Alabama. We followed the community engagement strategy approach to conduct our study.
View Article and Find Full Text PDFIntroduction: We hypothesized that pneumonitis during Pacific protocol (PDP) contributes to poor outcomes in patients with locally advanced non-small cell lung cancer (LANSCLC) treated with chemoradiation (ChRT) and durvalumab.
Methods: We analysed cases with LANSCLC extracted from a single academic institution database to identify patient, tumour, and treatment characteristics predicting for development of PDP and its effect on oncologic outcomes.
Results: Our database review identified 119 patients with LANSCLC that were treated with ChRT and durvalumab.